MimiVax Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Debt

  • Latest Deal Amount
  • $5.78M

  • Investors
  • 7

MimiVax General Information

Description

Developer of immunotherapeutic vaccines and targeted therapies intended to control tumor growth and recurrence. The company's vaccines use survivin-targeting technology to target a cell-survival protein present in most cancers, enabling healthcare providers to disrupt cancer, cure patients, and increase patient survival rates.

Contact Information

Website
www.mimivax.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Elm & Carlton Streets
  • Buffalo, NY 14263
  • United States
+1 (716)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Elm & Carlton Streets
  • Buffalo, NY 14263
  • United States
+1 (716)

MimiVax Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MimiVax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Debt - General 12-Jul-2024 $5.78M Completed Generating Revenue
8. Later Stage VC 09-Jan-2024 Completed Generating Revenue
7. Later Stage VC 10-Dec-2021 Completed Generating Revenue
6. Later Stage VC 24-Jun-2020 Completed Clinical Trials - Phase 2
5. Later Stage VC 02-Aug-2019 Cancelled Clinical Trials - Phase 2
4. Early Stage VC Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 25-Aug-2015 Completed Startup
2. Grant 01-Mar-2015 $2M $450K Completed Startup
1. Seed Round 01-Jan-2012 $450K $450K Completed Startup
To view MimiVax’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

MimiVax Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MimiVax Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
MEDA Angels Angel Group Minority
The Brain Tumor Investment Fund Not-For-Profit Venture Capital Minority
The Sontag Foundation Limited Partner Minority
Angel (individual) Minority
Varia Ventures Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

MimiVax FAQs

  • When was MimiVax founded?

    MimiVax was founded in 2011.

  • Where is MimiVax headquartered?

    MimiVax is headquartered in Buffalo, NY.

  • What is the size of MimiVax?

    MimiVax has 3 total employees.

  • What industry is MimiVax in?

    MimiVax’s primary industry is Drug Discovery.

  • Is MimiVax a private or public company?

    MimiVax is a Private company.

  • What is MimiVax’s current revenue?

    The current revenue for MimiVax is .

  • How much funding has MimiVax raised over time?

    MimiVax has raised $20.8M.

  • Who are MimiVax’s investors?

    MEDA Angels, The Brain Tumor Investment Fund, The Sontag Foundation, , and Varia Ventures are 5 of 7 investors who have invested in MimiVax.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »